应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
MTVA MetaVia Inc
休市中 02-06 16:00:00 EST
1.82
+0.09
+5.20%
盘后
1.85
+0.03
+1.65%
19:42 EST
最高
1.95
最低
1.76
成交量
22.79万
今开
1.81
昨收
1.73
日振幅
10.98%
总市值
583.89万
流通市值
416.49万
总股本
320.82万
成交额
42.32万
换手率
9.96%
流通股本
228.84万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
MetaVia Inc与Syntekabio合作AI建模获突破进展 确认Vanoglipel关键治疗靶点
美股速递 · 02-04 21:06
MetaVia Inc与Syntekabio合作AI建模获突破进展 确认Vanoglipel关键治疗靶点
MetaVia公布Da-1726代谢疾病一期B临床试验积极结果——显著血糖控制、直接肝脏效应突出、减重效果强劲且安全性良好
美股速递 · 01-05
MetaVia公布Da-1726代谢疾病一期B临床试验积极结果——显著血糖控制、直接肝脏效应突出、减重效果强劲且安全性良好
Metavia Inc.盘中异动 早盘急速下挫5.21%
市场透视 · 2025-11-12
Metavia Inc.盘中异动 早盘急速下挫5.21%
加载更多
公司概况
公司名称:
MetaVia Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
MetaVia Inc.于2008年11月10日在密歇根以Michigan Life Therapeutics, LLC (MLT)这个名字注册成立。NeuroBo Pharmaceuticals, Inc.是一家临床阶段的生物技术公司,主要致力于开发和商业化治疗心脏代谢疾病的新药物。NeuroBo有两个主要项目,重点治疗非酒精性脂肪性肝炎(NASH)、肥胖症和2型糖尿病(T2D)。
发行价格:
--
{"stockData":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":1.82,"timestamp":1770411600000,"preClose":1.73,"halted":0,"volume":227914,"hourTrading":{"tag":"盘后","latestPrice":1.85,"preClose":1.82,"latestTime":"19:42 EST","volume":4203,"amount":7644.4412,"timestamp":1770424924079,"change":0.03,"changeRate":0.016484,"amplitude":0.043956},"delay":0,"changeRate":0.05202312138728328,"floatShares":2288400,"shares":3208200,"eps":-11.363935,"marketStatus":"休市中","change":0.09,"latestTime":"02-06 16:00:00 EST","open":1.81,"high":1.95,"low":1.76,"amount":423229.93919939996,"amplitude":0.109827,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-11.363935,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":1.73,"preHourTrading":{"tag":"盘前","latestPrice":1.78,"preClose":1.73,"latestTime":"08:55 EST","volume":2049,"amount":3619.5828831,"timestamp":1770386111333,"change":0.05,"changeRate":0.028902,"amplitude":0.075145},"postHourTrading":{"tag":"盘后","latestPrice":1.85,"preClose":1.82,"latestTime":"19:42 EST","volume":4203,"amount":7644.4412,"timestamp":1770424924079,"change":0.03,"changeRate":0.016484,"amplitude":0.043956},"volumeRatio":0.479966},"requestUrl":"/m/hq/s/MTVA","defaultTab":"news","newsList":[{"id":"1150245570","title":"MetaVia Inc与Syntekabio合作AI建模获突破进展 确认Vanoglipel关键治疗靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1150245570","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150245570?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:06","pubTimestamp":1770210383,"startTime":"0","endTime":"0","summary":"MetaVia Inc公布其与Syntekabio持续合作中人工智能建模研究的积极成果。最新数据证实,双方共同开发的糖尿病肾病治疗药物Vanoglipel已通过AI模型精准锁定关键治疗靶点。\n这项突破性进展标志着AI驱动药物研发模式在复杂疾病领域的应用迈出重要一步。通过深度学习算法分析海量生物医学数据,研究团队成功验证了Vanoglipel作用于肾脏纤维化与炎症通路的核心机制。\n合作双方表示,该成果将显著加速Vanoglipel的临床前开发进程。AI建模不仅缩短了传统靶点确认周期,更通过多维度模拟预测了化合物与靶点相互作用的特异性,为后续药物优化提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"1148649541","title":"MetaVia公布Da-1726代谢疾病一期B临床试验积极结果——显著血糖控制、直接肝脏效应突出、减重效果强劲且安全性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1148649541","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148649541?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:30","pubTimestamp":1767619821,"startTime":"0","endTime":"0","summary":"MetaVia Inc宣布其针对代谢疾病的候选药物Da-1726在一期B期临床试验中取得具有统计学意义的积极数据。该试验结果显示,Da-1726不仅能有效调控血糖水平,还展现出对肝脏的直接作用机制。此外,受试者在接受治疗后出现显著的体重下降,同时药物整体安全性表现优异,未出现严重不良反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2583531690","title":"Metavia Inc.盘中异动 早盘急速下挫5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583531690","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583531690?lang=zh_cn&edition=full","pubTime":"2025-11-12 23:41","pubTimestamp":1762962109,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日23时41分,Metavia Inc.股票出现异动,股价快速下跌5.21%。Metavia Inc.股票所在的生物技术行业中,整体涨幅为0.88%。其相关个股中,Leap Therapeutics, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Lexaria Bioscience Corp C/Wts 14/01/2026 涨幅较大,Salarius Pharmaceuticals, Inc.、Leap Therapeutics, Inc.、Clearmind Medicine Inc.较为活跃,换手率分别为6158.01%、521.51%、381.17%,振幅较大的相关个股有Leap Therapeutics, Inc.、Salarius Pharmaceuticals, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 ,振幅分别为115.43%、47.96%、47.55%。Metavia Inc.公司简介:MetaVia Inc是一家临床阶段的生物技术公司,专注于开发治疗心脏代谢疾病的新型药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112234149a49cc80f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112234149a49cc80f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4202","MTVA","OXM","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurobopharma.com","stockEarnings":[{"period":"1week","weight":-0.251},{"period":"1month","weight":-0.7925},{"period":"3month","weight":-0.8178},{"period":"6month","weight":-0.7373},{"period":"1year","weight":-0.9086},{"period":"ytd","weight":-0.7838}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MetaVia Inc.于2008年11月10日在密歇根以Michigan Life Therapeutics, LLC (MLT)这个名字注册成立。NeuroBo Pharmaceuticals, Inc.是一家临床阶段的生物技术公司,主要致力于开发和商业化治疗心脏代谢疾病的新药物。NeuroBo有两个主要项目,重点治疗非酒精性脂肪性肝炎(NASH)、肥胖症和2型糖尿病(T2D)。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.000503},{"month":2,"riseRate":0.3,"avgChangeRate":0.020039},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.011768},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.143887},{"month":5,"riseRate":0.222222,"avgChangeRate":-0.109293},{"month":6,"riseRate":0.555556,"avgChangeRate":0.090563},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.026489},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.189997},{"month":9,"riseRate":0.4,"avgChangeRate":0.065402},{"month":10,"riseRate":0.2,"avgChangeRate":-0.186131},{"month":11,"riseRate":0.3,"avgChangeRate":-0.112358},{"month":12,"riseRate":0.1,"avgChangeRate":-0.160075}],"exchange":"NASDAQ","name":"MetaVia Inc","nameEN":"MetaVia Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MetaVia Inc(MTVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MetaVia Inc(MTVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MetaVia Inc,MTVA,MetaVia Inc股票,MetaVia Inc股票老虎,MetaVia Inc股票老虎国际,MetaVia Inc行情,MetaVia Inc股票行情,MetaVia Inc股价,MetaVia Inc股市,MetaVia Inc股票价格,MetaVia Inc股票交易,MetaVia Inc股票购买,MetaVia Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MetaVia Inc(MTVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MetaVia Inc(MTVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}